Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427454 | 0.98 | PPARG (0.37) | PPARGPPARAHSD11B1PDE4BMGLL | |
| SCHEMBL6424291 | 0.89 | AKR1C3 (0.39) | PPARGMGLLPTGDR2PTGS2AKR1C3 | |
| SCHEMBL6426727 | 0.88 | PPARG (0.38) | PPARGPPARAHSD11B1PDE4BMGLL | |
| SCHEMBL6425575 | 0.87 | AKR1C3 (0.39) | PPARGMGLLPTGDR2PTGS2AKR1C3 | |
| SCHEMBL6425959 | 0.87 | MEN1 (0.33) | HSD11B1AKR1C3AKR1C2 | |
| SCHEMBL6425986 | 0.86 | PPARG (0.38) | PPARGPPARAHSD11B1MGLLPTGDR2 | |
| SCHEMBL6424338 | 0.86 | PPARG (0.41) | PPARGPPARAPTGDR2PTGS2AKR1C3 | |
| SCHEMBL6425312 | 0.85 | PPARG (0.39) | PPARGPPARAHSD11B1PDE4BMGLL | |
| SCHEMBL6453546 | 0.85 | PDE2A (0.35) | MGLLAKR1C3AKR1C2 | |
| SCHEMBL6424162 | 0.85 | TSHR (0.35) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PPARG 1908/4885PPARA 2460/4885HSD11B1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.